The treatment, bamlanivimab and etesevimab administered together, was granted FDA emergency use authorization in February.
Eli Lilly and the FDA stipulated that the antibody cocktail is authorized as a COVID-19 prophylaxis only for individuals who have been exposed to the virus. They also said the treatment is not a substitute for a COVID-19 vaccine.
Eli Lilly’s antibody cocktail is the second to be granted emergency use authorization for post-exposure COVID-19 prophylaxis, as the FDA revised the emergency use authorization for Regeneron’s COVID-19 antibody cocktail, a combination of of casirivimab and imdevimab, in July.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
